Paper Details
- Home
- Paper Details
Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs.
Author: FeuersteinG, GagnonR, KosterP, ParsonsA A, RavalP, TilfordN, ValocikR
Original Abstract of the Article :
The effects of frovatriptan (VML 251/SB-209509) on coronary artery function were investigated in isolated coronary arteries from beagle dogs. Low concentrations of frovatriptan produced contraction with -logEC50 7.55 +/- 0.08 (n = 11). The maximal observed contraction attained was 56 +/- 7% of the c...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1097/00005344-199812000-00018
データ提供：米国国立医学図書館（NLM）
Frovatriptan: A New Antimigraine Agent with Potential Cardiovascular Benefits
Migraines are debilitating headaches that can significantly disrupt daily life. This study investigates the effects of frovatriptan, a novel antimigraine agent, on coronary artery function and overall cardiac function in dogs. The authors conducted both in vitro and in vivo experiments to assess the impact of frovatriptan on coronary blood flow and left ventricular function.
Frovatriptan: A Promising New Antimigraine Treatment
The study demonstrates that frovatriptan has the ability to relax coronary arteries in vitro and has no adverse effects on cardiac function in dogs. Furthermore, it shows that frovatriptan is superior to sumatriptan, another antimigraine agent, in terms of its impact on coronary blood flow after myocardial infarction. These findings suggest that frovatriptan may be a safer and more effective treatment option for migraines, potentially reducing the cardiovascular risks associated with some other antimigraine medications.
A New Oasis in the Desert of Migraine Treatment
This research provides valuable insights into the potential benefits of frovatriptan as a migraine treatment. The study's findings suggest that frovatriptan may offer a more favorable cardiovascular profile compared to other antimigraine agents, potentially reducing the risk of heart-related complications. This is a significant development in the search for safer and more effective treatments for migraines, offering a refreshing oasis in the desert of migraine research.
Dr.Camel's Conclusion
This research investigates the effects of frovatriptan, a novel antimigraine agent, on coronary artery function and overall cardiac function in dogs. The study's findings suggest that frovatriptan may be a safer and more effective treatment option for migraines, potentially reducing the cardiovascular risks associated with some other antimigraine medications. This is a promising development in the search for safer and more effective treatments for migraines, offering a refreshing oasis in the desert of migraine research.
Date :
- Date Completed 1999-03-05
- Date Revised 2019-07-24
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.